US-based Protalex has received approval from the French National Agency for Medicines and Health Products (ANSM) for its clinical trial application to begin a Phase Ib trial of its lead drug candidate PRTX-100.

PRTX-100 is a new-generation, immunomodulatory therapy and a highly purified form of Staphylococcal protein A (SpA), which is being evaluated to treat autoimmune diseases, such as rheumatoid arthritis (RA) and persistent / chronic immune thrombocytopenia (ITP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SpA is a bacterial protein demonstrated by Protalex and others to affect immune function in several preclinical trials.

The approval allows the company to start the trial (PRTX-100-203 Study) at several sites in France with patient enrolment expected to begin before the year-end.

In addition, the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending PRTX-100 for use as an orphan medicinal product to treat ITP.

See Also:

"The 203 Study is designed to evaluate the safety and efficacy of PRTX-100 in a range of doses."

The approval to start the trial and the positive COMP opinion follows the company’s previously announced initiation of a US Phase I / II clinical trial of PRTX-100 in adult ITP patients (PRTX-100-202 Study) and receipt of orphan drug designation (ODD) for the drug to treat ITP from the US Food and Drug Administration (FDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Protalex ITP Programmes vice-president Richard Francovitch said: "The 203 Study is designed to evaluate the safety and efficacy of PRTX-100 in a range of doses and, along with the recently initiated US-based 202 Study, will provide important data to support further development plans in ITP.

"Protalex is also very pleased to have received a positive opinion from the EMA COMP on the PRTX-100 application for ODD.

"Based on preclinical observations and data generated in prior clinical trials in patients with RA, we believe PRTX-100 represents a promising new approach for the treatment of ITP."

Approximately 30 patients will be enrolled in the open-label, dose-escalating 203 study in as many as five cohorts. Each patient will be given four, weekly intravenous doses of PRTX-100 and will be monitored for up to 48 weeks thereafter.

The trial’s primary endpoint is safety, while secondary endpoints include platelet response to PRTX-100, immunogenicity and pharmacokinetics.